Novavax: A Hand-Picked Vaccine on the Road Towards Human Clinical Trial Against Coronavirus

Novavax Identified an "Ideal" Coronavirus Vaccine Candidate
The news from Novavax (NVAX) informs that the firm has identified an "ideal" coronavirus vaccine candidate, NVX-CoV2373, that is a stable, prefusion protein made using Novavax’s proprietary nanoparticle technology. The firm will initiate a first-in-human trial in mid-May.

Novavax’s proprietary Matrix-M . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.